

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or non-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/

PCT**CHAPTER II****DEMAND**

under Article 31 of the Patent Cooperation Treaty:
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

| | |
|--|---|
| For International Preliminary Examining Authority use only | |
| Identification of IPEA | Date of receipt of DEMAND |
| Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION | |
| International application No. PCT/AU03/00053 | Applicant's or agent's file reference (Earliest) Priority date (day/month/year) 18 January 2002 |
| International filing date (day/month/year) 20 January 2003 | |
| Title of invention Magnesium-Zirconium Alloying | |
| Box No. II APPLICANT(S) | |
| Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) | |
| CAST CENTRE PTY LTD Cooper Road St Lucia QLD 4067 Australia | |
| Telephone No. | |
| Facsimile No. | |
| Teleprinter No. | |
| Applicant's registration No. with the Office | |
| State (that is, country) of nationality: Australia | |
| State (that is, country) of residence: Australia | |
| Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) | |
| QIAN, Ma 17 Hindmarsh Place Westlake QLD 4074 Australia | |
| State (that is, country) of nationality: Australia | |
| State (that is, country) of residence: Australia | |
| Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) | |
| STJOHN, David 26 Gladstone Street Indooroopilly QLD 4068 Australia | |
| State (that is, country) of nationality: Australia | |
| State (that is, country) of residence: Australia | |
| <input checked="" type="checkbox"/> Further applicants are indicated on a continuation sheet. | |

Form PCT/IPEA 201 (first sheet) (March 2001, reprint July 2003)

See Notes to the demand form

BEST AVAILABLE COPY

Sheet No. 2.

International application No.
PCT/AU03/00053

Continuation of Box No. 11 APPLICANT(S)

If none of the following sub-boxes is used, this sheet should not be included in the demand.

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

FROST, Malcolm Timothy
104 Creekside Street
Kenmore QLD 4069
AustraliaState (that is, country) of nationality:
AustraliaState (that is, country) of residence:
Australia

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

☐ Further applicants are indicated on another continuation sheet.

See Notes to the demand form

Form PCT-IPHA 401 (continuation sheet) (March 2001; reprint July 2003)

BEST AVAILABLE COPY

Sheet No. 3

International application No.
PCT/AU03/00053

Box No. III AGENT OR COMMON REPRESENTATIVE: OR ADDRESS FOR CORRESPONDENCE

The following person is ☒ agent ☐ common representativeand ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority. In addition to the agent(s)/common representative appointed earlier.Name and address: (Family name followed by given name; for a legal entity, full official designation.
The address must include postal code and name of country.)GRIFFITH HACK
167 Eagle Street
Brisbane QLD 4000
Australia

Telephone No.

07 3221 7200

Facsimile No.

07 3221 1245

Teleprinter No.

Agent's registration No. with the Office

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION

Statement concerning amendments:*

1. The applicant wishes the international preliminary examination to start on the basis of:

☐ the international application as originally filedthe description ☐ as originally filed☒ as amended under Article 34the claims ☒ as originally filed☐ as amended under Article 19 (together with any accompanying statement)☐ as amended under Article 34the drawings ☒ as originally filed☐ as amended under Article 342. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired.)

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: English

☒ which is the language in which the international application was filed.☐ which is the language of a translation furnished for the purposes of international search.☐ which is the language of publication of the international application.☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

Box No. V ELECTION OF STATES

The applicant hereby elects all eligible States that is, all States which have been designated and which are bound by Chapter II of the PCT

excluding the following States which the applicant wishes not to elect:

Sheet No. 4.

International application No.
PCT/AU03/00053

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- | | | | |
|--|---|-------|--------|
| 1. translation of international application | : | _____ | sheets |
| 2. amendments under Article 34 | : | 4 | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : | _____ | sheets |
| 4. copy (or, where required, translation) of statement under Article 19 | : | _____ | sheets |
| 5. letter | : | 1 | sheets |
| 6. other (specify): Statement of Amendments | : | 1 | sheets |

For International Preliminary
Examining Authority use only

| received | not received |
|--------------------------|--------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |

The demand is also accompanied by the item(s) marked below:

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> fee calculation sheet | 3. <input type="checkbox"/> statement explaining lack of signature |
| 2. <input type="checkbox"/> original separate power of attorney | 6. <input type="checkbox"/> sequence listings in computer readable form |
| 3. <input type="checkbox"/> original general power of attorney | 7. <input type="checkbox"/> tables in computer readable form related to sequence listings |
| 4. <input type="checkbox"/> copy of general power of attorney; reference number, if any: | 8. <input checked="" type="checkbox"/> other (specify): Article 34 Amendments |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).



Peter John WILLIAMS
Registered Patent Attorney of GRIFFITH HACK
for and on behalf of the Applicant

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.

☐ The applicant has been informed accordingly.

4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.

5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

Form PCT/HPEA/401 (last sheet) (January 2003, report July 2003)

BEST AVAILABLE COPY

10/501704

ARTICLE 34 AMENDMENTS - PCT/A 009/0055 DT94 Rev'd PCT/PTO 16 JUL 2004

Description:

Replace pages 1, 2, 3 and 7 with new pages 1, 2, 3 and 7 respectively.

The amendments are detailed below with added text underlined and deleted text placed within [] for ease of reference.

- The portion of the description originally featuring at page 1, lines 24 and 25 has been amended to read:

"temperature properties which are not readily achievable with the Mg-Al-Zn alloys."

- The portion of the description originally featuring at page 2, lines 27 - 36 has been amended to read:

"are generally made by chemical reduction by magnesium of salt mixtures based on zirconium fluorides or zirconium chlorides. [Both types of master alloy are essentially the same and contain about one third their weight of zirconium. One of them,] A master alloy, developed by Magnesium Elektron Ltd (MEL) in about 1945 via chemical reduction of a complex zirconium fluoride [with] by molten magnesium, has been long known as Zirmax (trade mark). A similar type of Mg-Zr master alloy was developed in the United States at about the same time based on a chloride salt reduction process."

- The portion of the description originally featuring at page 3, lines 9 - 12 has been amended to read:

"Prior to Zirmax type master alloys becoming [the] a standard source of zirconium for the production of zirconium-containing magnesium alloys, alloying with various forms of zirconium metal were investigated."

- The portion of the description originally featuring at page 7, lines 27 - 34 has been amended to read:

"The hydrofluoric acid preferably has a concentration between 0.1[0] % and 50[.0] %, more preferably between [0.50] 0.1 % and 5[.0] %, and most preferably between [1.5] 0.1 % and 2.5 %, with the acid concentrations calculated as shown later in this specification. These acid concentration ranges correspond respectively to about 0.05 - [50.0] 25 molar, [0.25] 0.05 - [2.63] 2.5 molar and [0.76 - 1.28] 0.05 - 1.25 molar, [which may be rounded to 0.05 - 50.0 molar, 0.25 - 3.0 molar and 0.75 - 1.5 molar.] Efficacy at concentrations less than 0.1% HF, for example 0.07% (about 0.035 molar), has been demonstrated.